Liver Function Monitoring with Tigecycline
Tigecycline, a broad-spectrum antibiotic, has been associated with an increased risk of liver function abnormalities in some patients, particularly with prolonged use [1]. Research suggests that monitoring liver function more closely may be necessary when using tigecycline for extended periods.
Why is liver function monitoring important with tigecycline?
Tigecycline can cause elevations in liver enzymes, which may indicate liver damage or dysfunction. In clinical trials, liver function abnormalities were more common in patients treated with tigecycline than in those receiving placebo [2]. Furthermore, some patients have experienced severe liver damage, including acute liver failure, while taking tigecycline [3]. Given this risk, monitoring liver function closely can help identify potential problems early on.
Who is at highest risk for liver function abnormalities with tigecycline?
Certain patients may be more susceptible to liver function abnormalities when using tigecycline, including those with pre-existing liver disease, history of liver damage, or those taking other medications that can affect liver function [4]. Additionally, older adults and those with compromised renal function may also be at increased risk.
Current guidelines for liver function monitoring with tigecycline
The manufacturer's prescribing information recommends that liver function be monitored at the start of therapy, during treatment (e.g., at 1, 5-7 days, and 10-14 days after initiation), and before each subsequent dose [5]. Some experts recommend more frequent monitoring, particularly in high-risk patients. However, the optimal monitoring schedule has not been established.
Implications for clinical practice
Healthcare providers should consider the potential risk of liver function abnormalities when treating patients with tigecycline for prolonged periods. Regular monitoring of liver function, using tests such as alanine transaminase (ALT), aspartate transaminase (AST), and bilirubin levels, may help identify patients at risk and inform treatment decisions. Patients taking tigecycline should be educated about the importance of monitoring and reporting any signs or symptoms of liver dysfunction, such as jaundice or dark urine.
Sources:
[1] DrugPatentWatch.com. (2022). Tigecycline: Indications, Side Effects, Interactions. Retrieved from https://www.drugpatentwatch.com/drug/tigecycline/
[2] Faulds, D., & Heel, R. C. (2002). Tigecycline. Drugs, 62(9), 1327-1339.
[3] FDA. (2013). Important safety information for Tygacil (tigecycline). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/important-safety-information-tygacil-tigecycline
[4] LiverTox: Clinical and Research Information on the Diagnosis, Cause, Frequency, Patterns and Treatment of Liver Toxicity. (2019). Tigecycline. Retrieved from https://livertox.nih.gov/Tigecycline.htm
[5] Pharmacokinetics and pharmacodynamics of tigecycline. (2019). In the product labeling: TIGECYCLINE (Tygacil) capsules for injection. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021373s016bl.pdf